Analytical Data
-
基因名
FBXO9
- Application
-
别名
Cross-immune reaction antigen 1; dJ341E18.2; DKFZp434C0118; F-box only protein 9; Fbp24; FBX09; FBX9; FBX9_HUMAN; Fbxo9; KIAA0936; NY REN 57; OTTHUMP00000016628; OTTHUMP00000016629; OTTHUMP00000214588; Renal carcinoma antigen NY-REN-57; VCIA1
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9UK97
-
表达区间
1-437aa
-
氨基酸序列
MAEAEEDCHSDTVRADDDEENESPAETDLQAQLQMFRAQWMFELAPGVSSSNLENRPCRAARGSLQKTSADTKGKQEQAKEEKARELFLKAVEEEQNGALYEAIKFYRRAMQLVPDIEFKITYTRSPDGDGVGNSYIEDNDDDSKMADLLSYFQQQLTFQESVLKLCQPELESSQIHISVLPMEVLMYIFRWVVSSDLDLRSLEQLSLVCRGFYICARDPEIWRLACLKVWGRSCIKLVPYTSWREMFLERPRVRFDGVYISKTTYIRQGEQSLDGFYRAWHQVEYYRYIRFFPDGHVMMLTTPEEPQSIVPRLRTRNTRTDAILLGHYRLSQDTDNQTKVFAVITKKKEEKPLDYKYRYFRRVPVQEADQSFHVGLQLCSSGHQRFNKLIWIHHSCHITYKSTGETAVSAFEIDKMYTPLFFARVRSYTAFSERPL
-
分子量
77.5 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FBXO9, a member of the F-box protein family, plays a critical role in the ubiquitin-proteasome pathway, which is essential for protein degradation and regulation of various cellular processes. The research on FBXO9 has gained significance due to its involvement in cell cycle regulation, apoptosis, and signal transduction, making it a potential target for cancer therapy. Abnormal expression or mutations in FBXO9 have been linked to several diseases, particularly malignancies, where it can act as either a tumor suppressor or an oncogene. The recombinant FBXO9 protein is used extensively in experimental studies to elucidate its function, interactions, and regulatory mechanisms at the molecular level. By producing FBXO9 in a recombinant form, researchers aim to investigate its structure-function relationship, identify its substrates, and explore its role in various signaling pathways. The ability to manipulate FBXO9 through recombinant technology holds promise for therapeutic applications, offering insights into the development of novel drugs targeting ubiquitin-mediated processes in cancer and other diseases. As the understanding of FBXO9 continues to evolve, its potential as a biomarker or therapeutic target remains a focal point of ongoing research in cell biology and oncology.
